

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

## **PW MEDTECH GROUP LIMITED**

### **普华和顺集团公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1358)**

## **SUPPLEMENTAL ANNOUNCEMENT RELATING TO THE MAJOR TRANSACTION DISPOSAL OF CBPO SHARES**

Reference is made to the announcements dated September 19, 2019, November 7, 2019 and January 23, 2020 and the circular (the “**Circular**”) dated October 18, 2019 of PW Medtech Group Limited (the “**Company**”) in relation to the Disposal. Capitalised terms used herein shall have the same meanings as defined in the Circular unless the context herein requires otherwise.

As disclosed in the Circular, the closing of the Disposal is conditional upon, among other things, the entry into the Merger Agreement (the “**Merger Agreement Condition**”), and all the conditions precedent set out in the Share Purchase Agreement can be waived by the Company and Centurium. The Board announces that after good and valuable consideration, the Company and Centurium entered into an amendment No. 2 to the Share Purchase Agreement on May 5, 2020 (the “**Amendment Agreement No. 2**”) to waive the Merger Agreement Condition.

The Board considered that the terms and conditions of the Amendment Agreement No. 2 did not constitute a material change to the provisions of the Share Purchase Agreement.

Save as disclosed above, all other provisions of the Share Purchase Agreement remain unchanged in all material aspects.

Pursuant to the Share Purchase Agreement (as amended and supplemented from time to time), before closing of the Disposal, Centurium may assign its rights and obligations under the Share Purchase Agreement to its affiliates without the prior written consent of the Company. On May 5, 2020, (i) Centurium, Point Forward Holdings Limited (an affiliate of Centurium, “**Point Forward**”) and the Company entered into an assignment agreement, pursuant to which Centurium assigned its rights to acquire 385,000 CBPO Shares under the Share Purchase Agreement to Point Forward; and (ii) Centurium, Double Double Holdings Limited (an affiliate of Centurium, “**Double Double**”) and the Company entered into an assignment agreement, pursuant to which Centurium assigned its rights to acquire 615,000 CBPO Shares under the Share Purchase Agreement to Double Double.

As at the date of this announcement, save for the Merger Agreement Condition which has been waived, all other conditions precedent of the Disposal have been fulfilled. Pursuant to the Share Purchase Agreement, the closing of the Disposal shall take place on the date that is the fifth (5th) business day following the date of this announcement or such other date as may be agreed by the Company and Centurium. Upon completion of the Disposal, such shareholding percentage of the Company in CBPO will decrease to 13.83%.

By order of the Board  
**PW Medtech Group Limited**  
**Yue'e Zhang**  
*Chairman & Chief Executive Officer*

Hong Kong, May 5, 2020

*As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Zhang Xingdong and Mr. Chen Geng.*